Search

Your search keyword '"Sindaco, Paola"' showing total 35 results
Start Over Author "Sindaco, Paola"
35 results on '"Sindaco, Paola"'

3. Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

Author

von Jan, Jana, Timonen, Sanna, Braun, Till, Jiang, Qu, Ianevski, Aleksandr, Peng, Yayi, McConnell, Kathleen, Sindaco, Paola, Müller, Tony Andreas, Pützer, Sabine, Klepzig, Hanna, Jungherz, Dennis, Dechow, Annika, Wahnschaffe, Linus, Giri, Anil K., Kankainen, Matti, Kuusanmäki, Heikki, Neubauer, Heidi A., Moriggl, Richard, Mazzeo, Paolo, Schmidt, Nicole, Koch, Raphael, Hallek, Michael, Chebel, Amel, Armisen, David, Genestier, Laurent, Bachy, Emmanuel, Mishra, Anjali, Schrader, Alexandra, Aittokallio, Tero, Mustjoki, Satu, and Herling, Marco

Published
2024
Full Text
View/download PDF

10. Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms

Author

Isabelle, Colleen, primary, Johnson, William T., additional, McConnell, Kathleen, additional, Vogel, Ashley, additional, Brammer, Jonathan E., additional, Boles, Amy, additional, Keller, Robyn, additional, Sindaco, Paola, additional, Nisenfeld, Liam, additional, Uppal, Guldeep, additional, Nikbakht, Neda, additional, Calabretta, Bruno, additional, Porazzi, Patrizia, additional, Gong, Jerald, additional, Chakravarti, Nitin, additional, Porcu, Pierluigi, additional, and Mishra, Anjali, additional

Published
2023
Full Text
View/download PDF

13. Hepatitis B Virus and B-cell Lymphoma: Evidence, Unmet Need, Clinical Impact, and Opportunities

Author

Rosenberg, Maya, Poluch, Maria, Thomas, Colin, Sindaco, Paola, Khoo, Alan, Porcu, Pierluigi, Rosenberg, Maya, Poluch, Maria, Thomas, Colin, Sindaco, Paola, Khoo, Alan, and Porcu, Pierluigi

Abstract

Nearly a billion people worldwide are infected with the hepatitis B Virus (HBV) and about a third of them have chronic infection. HBV is an important cause of morbidity and mortality, including acute and chronic hepatitis and hepatocellular carcinoma (HCC). Screening and control of primary HBV infection through vaccination represent a major advance in global public health, but large sections of the world population, in both developed and underdeveloped countries, remain unscreened and unvaccinated. In addition to being a global cause of liver disease, an important role of HBV in lymphoma has also emerged. First, the high risk of HBV reactivation in previously infected patients receiving chemo-immunotherapy necessitates the systematic evaluation of HBV serological status in all non-Hodgkin's lymphoma (NHL) cases and preemptive antiviral therapy for those who may have chronic or occult HBV infection. Second, HBV has been shown to infect lymphocytes, namely B-cells, and has been associated with a higher risk of developing B-cell lymphoma, most clearly in countries where HBV is endemic. While the risk of HBV reactivation with chemoimmunotherapy in NHL is well known, the role and the impact of HBV as a global lymphoma risk factor and potential oncogenic driver in B-cells are very poorly understood. Here, we review the clinical and scientific evidence supporting an association between HBV and B-cell lymphoma, with a particular focus on diffuse large B-cell lymphoma (DLBCL) and provide an overview of the estimated impact of HBV infection on the biology and clinical course of DLBCL. We also discuss ways to gain a better insight into the unmet need posed by HBV in lymphoma and whether assessing immune responses to HBV, measuring viral loads, and detecting the presence of HBV-encoded proteins in tumor tissue could be integrated into the molecular and clinical risk stratification of patients with DLBCL.

Published
2023

14. Preclinical Evaluation of Anti-CD38 Therapy in Mature T-cell Neoplasms

Author

Isabelle, Colleen, Johnson, William, McConnell, Kathleen, Vogel, Ashley, Brammer, Jonathan, Boles, Amy, Keller, Robyn, Sindaco, Paola, Nisenfeld, Liam, Uppal, Guldeep, Nikbakht, Neda, Calabretta, Bruno, Porazzi, Patrizia, Gong, Jerald, Chakravarti, Nitin, Porcu, Pierluigi, Mishra, Anjali, Isabelle, Colleen, Johnson, William, McConnell, Kathleen, Vogel, Ashley, Brammer, Jonathan, Boles, Amy, Keller, Robyn, Sindaco, Paola, Nisenfeld, Liam, Uppal, Guldeep, Nikbakht, Neda, Calabretta, Bruno, Porazzi, Patrizia, Gong, Jerald, Chakravarti, Nitin, Porcu, Pierluigi, and Mishra, Anjali

Published
2023

15. The Role of Interleukin-15 in the Development and Treatment of Hematological Malignancies

Author

Sindaco, Paola, Pandey, Hritisha, Isabelle, Colleen, Chakravarti, Nitin, Brammer, Jonathan Edward, Porcu, Pierluigi, Mishra, Anjali, Sindaco, Paola, Pandey, Hritisha, Isabelle, Colleen, Chakravarti, Nitin, Brammer, Jonathan Edward, Porcu, Pierluigi, and Mishra, Anjali

Abstract

Cytokines are a vital component of the immune system that controls the activation and growth of blood cells. However, chronic overexpression of cytokines can trigger cellular events leading to malignant transformation. The cytokine interleukin-15 (IL-15) is of particular interest, which has been shown to contribute to the development and progression of various hematological malignancies. This review will provide an overview of the impact of the immunopathogenic function of IL-15 by studying its role in cell survival, proliferation, inflammation, and treatment resistance. We will also review therapeutic approaches for inhibiting IL-15 in blood cancers.

Published
2023

17. Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins

Author

Raffaella Buzzetti, Gian Paolo Fadini, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Domenico Cucinotta, Gabellieri Enrico, Alpestre Mauro, Marangoni Alberto, Bassano del Grappa, Pagotto Uberto, Bongiorno Claudio, Gatta Concetta, Del Buono Andrea, Lamacchia Olga, Maiellaro Pasquale, Antenucci Daniela, Brandoni Gabriele, Borroni Francesca, Gregori Giovanna, Di Benedetto Antonino, Placentino Giuseppe, Cavalot Franco, Barale Cristina, Fadini Gian Paolo, Del Sindaco Paola, Di Loreto Chiara, Anichini Roberto, Citro Giuseppe, D'Angelo Paola, Carletti Silvia, Buzzetti Raffaella, Sterpetti Sara, Carmen Mignogna, Elli Paolo, Giuseppe Prosperini, Michele Sacco, and Giuseppe Lucisano

Subjects
Blood Glucose, Glycated Hemoglobin A, Basal insulin, Degludec 100, Effectiveness, Glargine 300, Safety, Switch, Type 2 diabetes, Humans, Hypoglycemic Agents, Insulin Glargine, Insulin, Long-Acting, Retrospective Studies, Diabetes Mellitus, Type 2, Hypoglycemia, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), Diabetes Mellitus, Insulin, Long-Acting, Glycated Hemoglobin, Nutrition and Dietetics, Cardiology and Cardiovascular Medicine, Type 2
Abstract

Data on second generation basal insulin (2BI) in people with type 2 diabetes (T2D) generated by clinical trials still need confirmation in real-world clinical settings. This study aimed at assessing the comparative effectiveness of 2BI [Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (Deg-100)] in T2D Italian patients switching from first generation basal insulins (1BI).This was a retrospective, non-inferiority, multicenter study. Patients switching to Gla-300 or Deg-100 from 1BI were 1:1 propensity score matched (PSM). Changes during 6 months in continuous endpoints were assessed through linear mixed models. Incidence rates (IR) of hypoglycemia (episodes per patient-months) were compared using Poisson regression. Each PSM cohort included 593 patients. HbA1c decreased from baseline (8.7%) to 6 months by -0.58% (95%CI -0.69;-0.47) in Gla-300 group and -0.50% (95%CI -0.61;-0.39) in Deg-100 group, confirming the non-inferiority of Gla-300 vs. Deg-100. No between-group differences emerged: FBG was reduced by about 20 mg/dl with both 2BI, mean dose of 2BI (24.5 U, 0.3 U/Kg at the first prescription) was suboptimally titrated during 6 months (+1.34 U in Gla-300 and + 1.76 U in Deg-100), body weight showed minor changes. IR of hypoglycemia54 mg/dl was 0.32 (95%CI 0.21; 0.49) in Gla-300 group and 0.19 (95%CI 0.11; 0.33) in Deg-100 group (p = 0.14).In subjects with T2D, switching to 2BI from 1BI was associated with similar improvements in glycemic control, low hypoglycemia rates and no weight gain in real-life setting. Clinical inertia, represented by late treatment intensification and suboptimal titration, represents a major issue in Italy.

Published
2022

29. Bone Involvement in Hodgkin’s Lymphoma: Clinical Features and Outcome

Author

Gaudio, Francesco, primary, Pedote, Pasquale, additional, Niccoli Asabella, Artor, additional, Ingravallo, Giuseppe, additional, Sindaco, Paola, additional, Alberotanza, Vito, additional, Perrone, Tommasina, additional, Laddaga, Fiomena Emanuela, additional, Rubini, Giuseppe, additional, Stabile Ianora, Amato Antonio, additional, and Specchia, Giorgina, additional

Published
2018
Full Text
View/download PDF

30. Optimization of Postprandial Blood Glucose with Lispro Insulin in T2DM

Author

TORLONE, ELISABETTA, CARLO, LALLI, DEL SINDACO, PAOLA, CIOFETTA, MARCO, and BOLLI, GEREMIA BRUNETTO

Subjects
Diabetes -- Research, Health
Abstract

To assess the effects of lispro (LP) vs human regular insulin (Hum-R) on postprandial (PP) plasma glucose (PG) in type 2 diabetes (T2DM), 11 T2DM patients (age 50 [+ or [...]

Published
1999

34. Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM

Author

Torlone, Elisabetta, primary, Pampanelli, Simone, additional, Lalli, Carlo, additional, Sindaco, Paola Del, additional, Vincenzo, Antonio Di, additional, Rambotti, Anna Maria, additional, Modarelli, Francesco, additional, Epifano, Lucilla, additional, Kassi, Giorgia, additional, Perriello, Gabriele, additional, Brunetti, Paolo, additional, and Bolli, Geremia, additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results